Frontiers in antiviral therapy and immunotherapy

Steven M. Heaton

Research output: Contribution to journalEditorialOtherpeer-review

1 Citation (Scopus)


Despite recent advances in the therapeutic control of immune function and viral infection, current therapies are often challenging to develop, expensive to deploy and readily select for resistance-conferring mutants. Shaped by the host-virus immunological ‘arms race’ and tempered in the forge of deep time, the biodiversity of our world is increasingly being harnessed for new biotechnologies and therapeutics. Simultaneously, a shift towards host-oriented antiviral therapies is currently underway. In this Clinical & Translational Immunology Special Feature, I outline a strategic vision integrating these themes to create a new generation of effective, economical and robust antiviral treatments and immunotherapies. Durable international cooperation over the coming decades is necessary to achieve this, so here I invite leading international experts to discuss frontiers in host-oriented therapies, methods for modulating immune gene expression and applications of recent genome sequencing technologies, including an emerging research field.
Original languageEnglish
Article numbere1115
Number of pages3
JournalClinical & Translational Immunology
Issue number2
Publication statusPublished - 19 Feb 2020


  • information economy paradox
  • antiviral
  • immunotherapy
  • post-transcriptional regulation
  • neo-virology
  • HIV
  • drug repurposing

Cite this